Maintenance of glycemic control with liraglutide vs oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME)
Diabetes, Obesity and Metabolism Oct 14, 2021
Unger J, Allison DC, Kaltoft M, et al. - Relative to oral antidiabetic drugs (OAD), liraglutide allows better control of glycemia. This supports the use of liraglutide when intensifying therapy in primary care patients with type 2 diabetes (T2D).
LIRA-PRIME (NCT02730377), a randomized open-label trial, included 1,991 adults with T2D (glycated hemoglobin [HbA1c] 7.5–9.0%) receiving metformin.
Participants were randomized 1:1 to liraglutide (≤ 1.8 mg/day) or one OAD, selected by the investigator, added to metformin, for up to 104 weeks.
With liraglutide vs OAD, 44 weeks longer median time to inadequate glycemic control was recorded (109 weeks [25% percentile, 38; 75% percentile, not available] vs 65 weeks [25% percentile, 35; 75% percentile, 107]).
Liraglutide was significantly favored over OAD by the changes in HbA1c and body weight at Week 104/premature treatment discontinuation.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
